FN2 Earnings Intelligence

Axsome Therapeutics, Inc. earnings overview

Latest Axsome Therapeutics, Inc. (AXSM) earnings intelligence, including the newest scorecard, market reaction, and transcript analysis.

Next reportAxsome Therapeutics, Inc. reports Monday, Nov 2, 2026 · Before market openConsensus EPS $-0.49 · consensus revenue $258.3M
AXSM FY2026 Q2 · Calendar Q3 2026

Axsome Therapeutics, Inc.

The quarter supports a constructive but conditional view: AUVELITY-led growth, expanding market access, and pipeline advancement strengthen Axsome’s trajectory, but below-consensus EPS and revenue, commercialization economics, and regulatory execution keep the case dependent on continued delivery.

EPS surprise-11.0%
Market move+3.8%

Get the AXSM recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.